Skip to main content
Terug
VRBCF logo

Virbac S.A.

Datakwaliteit: 100%
Overbought
VRBCF
OTC Healthcare Drug Manufacturers - General
€ 384,75
€ 0,00 (0,00%)
Marktkapitalisatie: 3,22B
Dagbereik
€ 384,75 € 431,80
52-Weeksbereik
€ 324,00 € 431,80
Volume
1
50D / 200D Gem.
€ 346,00 / € 346,00
Vorige Slotkoers
€ 384,75

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 21,4 0,3
P/B 2,9 2,9
ROE % 13,9 3,7
Net Margin % 10,3 3,8
Rev Growth 5Y % 8,3 10,0
D/E 0,3 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,00
€ 0,00 – € 0,00
1,9 B 0
FY2029 € 24,09
€ 23,75 – € 24,70
1,8 B 1
FY2028 € 24,69
€ 24,35 – € 25,32
1,7 B 1

Belangrijkste Punten

Revenue grew 8,31% annually over 5 years — modest growth
ROE of 13,91% — decent returns on equity
Debt/Equity of 0,26 — conservative balance sheet
Generating 103,37M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,53%
Capital efficient — spends only 6,30% of revenue on capex

Groei

Revenue Growth (5Y)
8,31%
Revenue (1Y)4,78%
Earnings (1Y)3,81%
FCF Growth (3Y)15,42%

Kwaliteit

Return on Equity
13,91%
ROIC11,52%
Net Margin10,30%
Op. Margin14,89%

Veiligheid

Debt / Equity
0,26
Current Ratio1,53
Interest Coverage25,29

Waardering

P/E Ratio
21,37
P/B Ratio2,87
EV/EBITDA15,57
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4,78% Revenue Growth (3Y) 8,36%
Earnings Growth (1Y) 3,81% Earnings Growth (3Y) 11,51%
Revenue Growth (5Y) 8,31% Earnings Growth (5Y) 7,45%
Profitability
Revenue (TTM) 1,46B Net Income (TTM) 150,83M
ROE 13,91% ROA 7,88%
Gross Margin 35,36% Operating Margin 14,89%
Net Margin 10,30% Free Cash Flow (TTM) 103,37M
ROIC 11,52% FCF Growth (3Y) 15,42%
Safety
Debt / Equity 0,26 Current Ratio 1,53
Interest Coverage 25,29 Dividend Yield 0,00%
Valuation
P/E Ratio 21,37 P/B Ratio 2,87
P/S Ratio 2,20 PEG Ratio 4,51
EV/EBITDA 15,57 Dividend Yield 0,00%
Market Cap 3,22B Enterprise Value 3,40B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,46B 1,40B 1,25B 1,22B 1,06B
Net Income 150,83M 145,29M 121,30M 121,97M 113,16M
EPS (Diluted) 17,98 17,34 14,38 14,43 13,40
Gross Profit 517,74M 937,60M 809,60M 794,99M 712,85M
Operating Income 218,07M 227,50M 184,88M 179,52M 167,63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,91B 1,85B 1,46B 1,33B 1,20B
Total Liabilities 788,89M 805,12M 545,81M 494,53M 476,36M
Shareholders' Equity 1,12B 1,04B 900,30M 839,33M 724,94M
Total Debt 295,15M 307,01M 120,11M 90,40M 94,47M
Cash & Equivalents 122,45M 149,63M 175,91M 177,38M 172,79M
Current Assets 791,59M 844,12M 771,48M 723,53M 624,67M
Current Liabilities 516,12M 464,56M 399,05M 390,59M 370,75M